20/20 Biolabs, Inc.

AIDX · NasdaqCM · Stock · Healthcare

$0.26

-5.27% today

Delayed price, 2026-10-17 05:22 UTC

What 20/20 Biolabs does

20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Key facts

Sector

Healthcare

Industry

Medical Devices

Market cap

$3.3M

P/E (ttm)

—

Forward P/E

—

Dividend yield

0.00%

Beta

—

Profit margin

-285.0%

Employees

Headquarters

Gaithersburg, MD, United States

Exchange

NasdaqCM

Website

2020biolabs.com

Performance

1 Month

-44.6%

3 Months

-49.9%

6 Months

-85.4%

1 Year

-98.2%

5 Years

-86.1%

$0.2652-week range$50.00

Biggest setback — last 12 months

-98.2%

16 Feb 2026 → 12 Oct 2026

Fell from $14.78 to $0.26 — its sharpest sustained decline this year.

Biggest run-up — last 12 months

+44.2%

27 Jul 2026 → 24 Aug 2026

Ran from $0.43 to $0.62 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Mixed

Price is not consistently aligned with its short- and long-term averages.

Horizon	Bear case (−1σ)	Base case	Bull case (+1σ)
1 Month	$0.18 (-29.4%)	$0.26	$0.37 (+41.6%)
3 Months	$0.14 (-45.3%)	$0.26	$0.48 (+82.7%)
6 Months	$0.11 (-57.3%)	$0.26	$0.61 (+134.5%)
12 Months	$0.08 (-70.0%)	$0.26	$0.87 (+233.8%)

Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 120.5%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

UEEC

United Health Products, Inc.

Recent headlines

Healwell AI (TSX:AIDX) Stock Draws Fresh Price Target Split After Quarterly Results — Simply Wall St.

Recent insider activity

Acquired 100,000 shares — Bergman Alan B., Chief Financial Officer · 2026-04-06

Acquired 150,000 shares — Zhou Jiming, Chief Operating Officer · 2026-04-06

Acquired 352,936 shares — Cohen Jonathan M, Chief Executive Officer · 2026-03-04

Acquired 19,164 shares — Rollins John Woodson, Director · 2026-02-23

Acquired 31 shares — Ross Michael A., Director · 2026-02-23

Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

What is a stock? Understanding risk and reward Why diversification matters

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.